ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      0.00
      0.00%
      US Tech 100
      21,214.46
      1.06%
      Dow Jones
      44,156.73
      0.30%
      Brent Oil
      78.075
      -0.33%
      Bitcoin
      102,350.87
      -1.24%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. Spineway (ALSPW) Quote

      Spineway

      Spineway (ALSPW)

      EU
      0.132
      0.0319
      (31.87%)
      Closed January 22 11:30AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      0.132
      Bid
      0.132
      Ask
      0.138
      Volume
      3,722,286
      0.099 Day's Range 0.139
      0.0008 52 Week Range 6.40
      Market Cap
      36.3
      Previous Close
      0.1001
      Open
      0.1029
      Last Trade
      1
      @
      0.132
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      1,215,038
      Shares Outstanding
      275
      Dividend Yield
      -
      PE Ratio
      0.00
      Earnings Per Share (EPS)
      -23.67k
      Revenue
      10.74M
      Net Profit
      -6.51M

      About Spineway

      Sector
      Home Health Care Services
      Industry
      Home Health Care Services
      Website
      www.spineway.com
      Headquarters
      Lyon, Rhone, Fra
      Founded
      -
      Spineway is listed in the Home Health Care Services sector of the Euronext with ticker ALSPW. The last closing price for Spineway was 0.10 €. Over the last year, Spineway shares have traded in a share price range of 0.0008 € to 6.40 €.

      Spineway currently has 275 shares outstanding. The market capitalization of Spineway is 27.53 € . Spineway has a price to earnings ratio (PE ratio) of 0.00.

      Ask ADVFN Intelligence (AI)

      ALSPW Latest News

      More News

      SPINEWAY : Résultats du 1er semestre 2022 et stratégie groupe

      SPINEWAY : Résultats du 1er semestre 2022 et stratégie groupe Communiqué de presse         Ecully, le 7 septembre 2022 –20h Résultats semestriels 2022 Premiers effets positifs du...

      September 07 2022
      GlobeNewswire Inc.

      Approbation par l'Assemblée Générale Extraordinaire du regroupement d'actions

      Approbation par l'Assemblée Générale Extraordinaire du regroupement d'actions Communiqué de presse         Ecully, le 26 juillet 2022 –8h30 Lancement d’un regroupement d’actions...

      July 26 2022
      GlobeNewswire Inc.

      Acquisition de Spine Innovations, entité spécialisée dans les prothèses de disque

      Acquisition de Spine Innovations, entité spécialisée dans les prothèses de disque Communiqué de presse         Ecully, le 21 juillet 2022 – 18h   Poursuite de la stratégie de croissance...

      July 21 2022
      GlobeNewswire Inc.

      Reprise de l'activité : Un 1er semestre 2022 en nette progression

      Reprise de l'activité : Un 1er semestre 2022 en nette progression Communiqué de presse         Ecully, le 13 juillet 2022 – 18h Chiffre d’affaires du 1er semestre 2022 : + 65...

      July 13 2022
      GlobeNewswire Inc.

      New development dynamics and confirmed business strategy

      New development dynamics and confirmed business strategy Press release         Ecully, June 24th, 2022 – 5.45pm New momentum for a strong comeback on the French market Successful...

      June 24 2022
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.036237.78705636740.09580.1390.098167000.10017366DE
      40.050561.9631901840.08150.1390.0816174380.09473879DE
      12-0.0269-16.92888609190.15890.160.07312150380.10710643DE
      26-0.413-75.77981651380.5450.650.0736982950.14531609DE
      520.1309119000.00116.40.0008141425020.01173313DE
      1560.1312164000.00086.60.0001502277080.00209498DE
      2600.12531870.149253730.00676.60.0001993477900.0022416DE

      ALSPW - Frequently Asked Questions (FAQ)

      What is the current Spineway share price?
      The current share price of Spineway is 0.132 €
      How many Spineway shares are in issue?
      Spineway has 275 shares in issue
      What is the market cap of Spineway?
      The market capitalisation of Spineway is EUR 27.53
      What is the 1 year trading range for Spineway share price?
      Spineway has traded in the range of 0.0008 € to 6.40 € during the past year
      What is the cash to sales ratio of Spineway?
      The cash to sales ratio of Spineway is 0
      What is the reporting currency for Spineway?
      Spineway reports financial results in EUR
      What is the latest annual turnover for Spineway?
      The latest annual turnover of Spineway is EUR 10.74M
      What is the latest annual profit for Spineway?
      The latest annual profit of Spineway is EUR -6.51M
      What is the registered address of Spineway?
      The registered address for Spineway is 7 ALLEE MOULIN BERGER,BATIMENT 7, LYON, RHONE, 69130
      What is the Spineway website address?
      The website address for Spineway is www.spineway.com
      Which industry sector does Spineway operate in?
      Spineway operates in the HOME HEALTH CARE SERVICES sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ALMASMastrad
      0.0218 €
      (122.45%)
      		24.21M
      MLAATAzorean Tech
      0.16 €
      (60.00%)
      		1.05k
      CDUConduril Engenharia SA
      24.60 €
      (30.16%)
      		150
      ALNMRNamR SA
      0.1745 €
      (29.74%)
      		46.73k
      ALSPWSpineway
      0.129 €
      (28.87%)
      		960.57k
      HYPDSHipay Group DS
      0.0002 €
      (-98.18%)
      		115.57k
      MLWEYWeya
      0.015 €
      (-42.31%)
      		30.9k
      DMSBSDiagnostic Medical Systems
      0.0045 €
      (-35.71%)
      		7.54k
      DRVDSDrone Volt DS
      0.0007 €
      (-22.22%)
      		143.64k
      POXELPoxel
      0.31 €
      (-20.61%)
      		2.9M
      ATOAtos SE
      0.0022 €
      (0.00%)
      		301.81M
      BCPBanco Comercial Portugues SA
      0.5132 €
      (0.16%)
      		35.61M
      ALMASMastrad
      0.0218 €
      (122.45%)
      		24.21M
      ALVERVergnet
      0.0014 €
      (0.00%)
      		17.57M
      ALCYBCybergun
      0.0001 €
      (0.00%)
      		15.68M

      Discussion

      View Full Feed
      Hardazoak Hardazoak 5 minutes ago
      Current Aabbg works fine, wallet works fine. New aabb wallet 2.0 with AI and moonpay exchange integrated coming. Stop with the lies gitreal, only you are believing your own lies.
      AABB
      KPIFF-LDDFF KPIFF-LDDFF 5 minutes ago
      KPIFF
      wadegarret wadegarret 5 minutes ago
      Novice- AI stocks have mostly done their thing

      I don't believe Stargate will add all that much to boost valuations further. I mean NVDA already sells for over a 30 something PE going forward, CRDO sells for an 85 PE going forward, CRWD sells for around an 80 PE going forward, PLTR
      AES CRDO CRWD
      PEACHMAN PEACHMAN 6 minutes ago
      The exact opposite of what you say is true.LOLOLOLOL!!!!! I OWN you, kitty. Heart, mind, body and soul!! You fall into traps, you copy verbatim my posts. Have you ever had an independent thought in your life?

      https://investorshub.advfn.com/uimage/uploads/2025/1/22/sdlmono_panther.pn
      IFUS
      pinhigh pinhigh 6 minutes ago
      Well done video gimmee! RRX!
      BIEL
      Orange Cassidy Orange Cassidy 8 minutes ago
      The Jared "whisperer" is still here in emoji form on every post. He has not gone anywhere. As it stands the mills are abandoned and this is still a sham. "Whats not to like?"
      NBRI
      bas2020 bas2020 8 minutes ago
      Any shorting after approval will be total manipulation by the corrupt cabal... your bosses. Hopefully, we'll have MTD denial prior with a cease and desist order to go with it... to cut ya all off at the knees. 💥
      NWBO
      hssbwwmp hssbwwmp 8 minutes ago
      Yes, I've seen them cite those factors in their reports as well as being flexible to adapt to them. So, it would seem that if AXXA was still able to grow revenue and reduce debt despite those factors, then the PPS should not have continued this long downtrend, correct? Something still is not comp
      AXXA
      RichieBoy RichieBoy 9 minutes ago
      Minute 28 - Minute 40 is on AI

      Keep in mind this is acutely political. So you'll be left wondering about this side of AI and oh that part of AI why aren't they important. They are important of course, but never before to date will you have seen such intense focus on this one facet.
      AFFU
      boarddork boarddork 10 minutes ago
      That’s a lot of push pins and zig zag strings to make that ultimate conclusion.
      COOP
      weedtrader420 weedtrader420 11 minutes ago
      BITCOIN XRP TRIUMPH MAGIC POWER $120,000 TARGET
      BTCUSD
      janice shell janice shell 11 minutes ago
      She's one of the very few who actually deserves a pardon.
      Hoskuld Hoskuld 12 minutes ago
      This is not really true Boi - although I can imagine that logically it should be true. But, no 2 companies run their trials the same way. Usually. this is deliberate. The FDA cannot evaluate them the same way, as a result. The guidelines are NOT requirements. They are simply suggestions.
      AVXL
      StayHumble StayHumble 13 minutes ago
      wow💹100% Xpert SHORT interest💹significant evidence of SHORTS💹💹 huzzah!!!
      HMBL
      WALL STREET KID WALL STREET KID 13 minutes ago
      $AMC 5B SWAPS EXPIRING! SHORTS AT RISK! Short Squeeze Update

      https://youtu.be/eUD6PpQ-Oxw?si=QpOWsGLt0b2Qu2s6
      AMC
      vinmantoo vinmantoo 16 minutes ago
      Jq1234, give Bluesky a try. It looks a lot like Twitter did but doesn’t have a controlling algorithm.
      WhAtEvA1 WhAtEvA1 16 minutes ago
      With 18 indications trial starting in India well ahead of US trials (and if proven successful) it won't take long when Vivos valuations will be trading forward. IMHO of course. It is worth bios do when efficacy data is strong and potential of approval in the public interest outweighs the risks.
      RDGL
      glens0 glens0 17 minutes ago
      $CTOR Not to many shares left in the market. Should go up real fast when good news comes out. And it should be soon.
      Total Insider Shares Held 64.72M
      Citius Oncology Annual Shares Outstanding
      (Millions of Shares)
      2024 68M
      CTOR
      Zorch305 Zorch305 18 minutes ago
      Whats 305
      RNVA
      theorysuit theorysuit 19 minutes ago
      You keep pointing to this journal as if that leads to approval. I think i told you this, this journal was meant to explain this garbage trial.....Pointing to the scoreboard. Any approvals? Over 20 years since this trial was started, 6 years since it has ended, and 4.5 years since data lock. NO
      NWBO
      WHITTENHALLJR WHITTENHALLJR 19 minutes ago
      Yes I bet it 2x better then before strap in stock-nuts
      CLHI

      Your Recent History

      EU
      ALSPW
      Spineway
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads